Advertisement

Der Kardiologe

, Volume 4, Issue 6, pp 441–473 | Cite as

Fahreignung bei kardiovaskulären Erkrankungen

  • H.H. KleinEmail author
  • A. Krämer
  • B.M. Pieske
  • H.-J. Trappe
  • H. de Vries
Positionspapier

Zusammenfassung

Die allgemeinen Regelungen für die Teilnahme am Straßenverkehr in der Bundesrepublik Deutschland sind in der Fahrerlaubnisverordnung (FeV) festgelegt. Für einen behandelnden Arzt besteht Aufklärungspflicht über die fehlende Fahreignung eines Patienten in seinem medizinischen Fachgebiet. Diese Aufklärung ist zu dokumentieren. Zusätzlich zu den gesetzlichen Vorgaben der FeV wird die Fahreignung bei Erkrankungen des Herz-Kreislauf-Systems in den Begutachtungsleitlinien zur Kraftfahrereignung des Gemeinsamen Beirats für Verkehrsmedizin behandelt. Da die FeV nur auf wenige kardiovaskuläre Erkrankungen eingeht und die Begutachtungsleitlinie nicht mehr dem aktuellen Stand des medizinischen Wissens entspricht, wurde im Auftrag der Deutschen Gesellschaft für Kardiologie das Positionspapier „Fahreignung bei kardiovaskulären Erkrankungen“ erstellt. Dieses Positionspapier beschreibt unter Berücksichtigung des aktuellen Wissenstandes die Bedingungen, wann bei Herzrhythmusstörungen, Synkopen, koronarer Herzerkrankung, Herzinsuffizienz und arterieller Hypertonie zeitlich begrenzt oder dauerhaft keine Fahreignung vorliegt.

Schlüsselwörter

Fahreignung Herzrhythmusstörungen Synkopen Herzinfarkt Herzinsuffizienz 

Fitness to drive and cardiovascular diseases

Abstract

The general rules governing participation in road traffic in Germany are defined in the driver’s license law. Attending physicians are obligated to determine if a patient lacks the ability to drive from the perspective of their medical specialty. This assessment must be documented. In addition to the legal requirements laid down in the driver’s license law, the driving ability of patients with cardiovascular diseases is covered in the guideline on expert opinions appraising driving capability as specified by the Advisory Board for Traffic Medicine. Since the driver’s license law only addresses a few cardiovascular disorders and the guideline on expert opinions no longer reflects the current standard of medical knowledge, a position paper on fitness to drive and cardiovascular diseases was formulated on behalf of the German Cardiac Society. Taking the current level of knowledge into consideration, this position paper describes the conditions when cardiac arrhythmias, syncopes, coronary heart disease, cardiac insufficiency, and arterial hypertension represent grounds for establishing temporary or permanent inability to drive.

Keywords

Fitness to drive Rhythm disturbance Syncope Myocardial infarction Heart failure 

Notes

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Literatur

  1. 1.
    Lewrenz H, Jagow FJ, Eggersmann A et al (2000) Bundesanstalt für Straßenwesen: Begutachtungsleitlinien zur Kraftfahrereignung. Berichte der Bundesanstalt für Straßenwesen, Mensch und Sicherheit, Heft M 115, Wirtschaftsverlag NW, Verlag für neue Wissenschaft GmbH, Postfach 101110, 27511 BremerhavenGoogle Scholar
  2. 2.
    Bundesministerium der Justiz (2009) Verordnung über die Zulassung von Personen zum Straßenverkehr (Fahrerlaubnisverordnung – FeV, 1.09.2009). http://bundesrecht.juris.de/fev/BJNR221410998.htmlGoogle Scholar
  3. 3.
    Petch MC (on behalf of the task force, 1998) Driving and heart disease. Eur Heart J 19:1165–1177Google Scholar
  4. 4.
    Simpson C, Dorian P, Gupta A et al (2004) Assessment of the cardiac patient for fitness to drive: Drive subgroup executive summary. Can J Cardiol 20:1314–1320. Die kompletten Ausführungen sind im Internet unter http://www.ccs.ca erhältlichGoogle Scholar
  5. 5.
    Öström M, Eriksson A (1987) Natural death while driving. J Forensic Sci 32:988–998PubMedGoogle Scholar
  6. 6.
    Cantor WJ, Fitchett D, Borgundvaag B et al (2009) For the TRANSFER-AMI trial investigators routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med 360:2705–2718CrossRefPubMedGoogle Scholar
  7. 7.
    Müller D, Agrawal R, Arntz H-R (2006) How sudden is sudden cardiac death? Circulation 114:1146–1150CrossRefPubMedGoogle Scholar
  8. 8.
    Kubitzki J, Janitzek T (2009) Sicherheit und Mobilität älterer Verkehrteilnehmer. Allianz Deutschland AG, Fritz-Schäffer-Str. 9, D-81737 München, DeutschlandGoogle Scholar
  9. 9.
    Wood KA, Drew BJ, Scheinman MM (1997) Frequency of disabling symptoms in supraventricular tachycardia. Am J Cardiol 79:145–149CrossRefPubMedGoogle Scholar
  10. 10.
    Clague JR, Dagres N, Kottkamp H et al (2001) Targeting the slow pathway for atrioventricular nodal reentrant tachycardia: initial results and longterm follow-up in 379 consecutive patients. Eur Heart J 22:82–88CrossRefPubMedGoogle Scholar
  11. 11.
    Klein GJ, Bashore TM, Sellers TD et al (1979) Ventricular fibrillation in the Wolff-Parkinson-White syndrome. N Engl J Med 301:1080–1085CrossRefPubMedGoogle Scholar
  12. 12.
    Munger TM, Packer DL, Hammill SC et al (1993) A population study of the natural history of Wolff-Parkinson-White syndrome in Olmsted County, Minnesota 1953–1989. Circulation 87:866–873PubMedGoogle Scholar
  13. 13.
    Pietersen AH, Damgaard Andersen E, Sandoe E (1992) Atrial fibrillation in the Wolff-Parkinson-White syndrome. Am J Cardiol 70:38A–43ACrossRefPubMedGoogle Scholar
  14. 14.
    Antz M, Weiss C, Volkmer M et al (2002) Risk of sudden death after successful accessory atrioventricular pathway ablation in resuscitated patients with Wolff-Parkinson-White syndrome. J Cardiovasc Electrophysiol 13:231–236CrossRefPubMedGoogle Scholar
  15. 15.
    Kose S, Amasyali B, Aytemir K et al (2005) Radiofrequency catheter ablation of accessory pathways during pre-excited atrial fibrillation: acute success rate and long-term clinical follow-up results as compared to those patients undergoing successful catheter ablation during sinus rhythms. Heart Vessels 20:142–146CrossRefPubMedGoogle Scholar
  16. 16.
    Rybak K, Nowak B, Pfeiffer D et al (2008) Kommentar zu den ESC-Leitlinien „Guidelines for cardiac pacing and cardiac resynchronization therapy“. Kardiologe 2:463–478CrossRefGoogle Scholar
  17. 17.
    Tang ASL, Roberts RS, Kerr C et al (2001) Relationship between pacemaker dependency and the effect of pacing mode on cardiovascular outcomes. Circulation 103:3081–3085PubMedGoogle Scholar
  18. 18.
    Connolly SJ, Kerr CR, Gent M et al (2000) Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. N Engl J Med 342:1385–1391CrossRefPubMedGoogle Scholar
  19. 19.
    Maisel WH (2006) Pacemaker and ICD generator reliability. JAMA 295:1929–1934CrossRefPubMedGoogle Scholar
  20. 20.
    Hauser RG, Hayes DL, Kallinen LM et al (2007) Clinical experience with pacemaker pulse generators and transvenous leads: an 8-year prospective multicenter study. Heart Rhythm 4:154–160CrossRefPubMedGoogle Scholar
  21. 21.
    Pavlovic SU, Kocovic D, Djordjevic M et al (1991) The etiology of syncope in pacemaker patients. PACE 14:2086–2091PubMedGoogle Scholar
  22. 22.
    Sgarbossa EB, Pinski SL, Jaeger FJ et al (1992) Incidence and predictors of syncope in paced patients with sick sinus syndrome. PACE 15 Part II:2055–2060Google Scholar
  23. 23.
    Platt S, Furman S, Gross JN et al (1996) Transtelephone monitoring for pacemaker follow-up 1981–1994. PACE 19:2089–2098PubMedGoogle Scholar
  24. 24.
    Wiegand UK, Bode F, Bonnemeier H et al (2003) Long-term complication rates in ventricular, single lead VDD, and dual chamber pacing. PACE 26:1961–1969PubMedGoogle Scholar
  25. 25.
    Moya A für die task force for the diagnosis and management of syncope of the European Society of Cardiology (ESC) (2009) Guidelines for the diagnosis and management of syncope (version 2009). Eur Heart J 30:2631–2671CrossRefPubMedGoogle Scholar
  26. 26.
    Gardner RA, Kruyer WB, Pickard JS, Celio PV (2000) Nonsustained ventricular tachycardia in 193 U.S. military aviators: long-term follow up. Aviat Space Environ Med 71:783–790PubMedGoogle Scholar
  27. 27.
    Altemose GT, Buxton AE (1999) Idiopathic ventricular tachycardia. Annu Rev Med 50:159–177CrossRefPubMedGoogle Scholar
  28. 28.
    Epstein AE für die Task Force ACC/AHA/HRS (2008) Guidelines for device-based therapy of cardiac rhythm abnormalities. Circulation 117:e350–e408 (http://circ.ahajournals.org/cgi/content/full/circulationaha;120/5/e34)Google Scholar
  29. 29.
    Frolkis JP, Pothier CE, Blackstone EH, Lauer MS (2003) Frequent ventricular ectopy after exercise as a predictor of death. N Engl J Med 348:781–790CrossRefPubMedGoogle Scholar
  30. 30.
    Buxton AE, Lee KL, DiCarlo L et al (2000) Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. N Engl J Med 342:1937–1945CrossRefPubMedGoogle Scholar
  31. 31.
    Gomes JA, Hariman RI, Kang PS et al (1984) Programmed electrical stimulation in patients with high-grade ventricular ectopy: electrophysiologic findings and prognosis for survival. Circulation 70:43–51PubMedGoogle Scholar
  32. 32.
    Della Bella P, De Ponti R, Uriarte JAS et al (2002) Catheter ablation and antiarrhythmic drugs for haemodynamically tolerated post-infarction ventricular tachycardia. Eur Heart J 23:414–424CrossRefGoogle Scholar
  33. 33.
    Grimm W, Christ M, Bach J et al (2003) Noninvasive arrhtyhmia risk stratification in idiopathic dilated cardiomypathy. Results of the Marburg Cardiomyopathy Study. Circulation 108:2883–2891CrossRefPubMedGoogle Scholar
  34. 34.
    Kadish A, Dyer A, Daubert JP et al (2004) Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomypathy. N Engl J Med 350:2151–2158CrossRefPubMedGoogle Scholar
  35. 35.
    Jung W, Lüderitz B (1996) Quality of life and driving in recipients of the implantable cardioverter-defibrillator. Am J Cardiol 78:51–56CrossRefPubMedGoogle Scholar
  36. 36.
    Vijgen J, Botto G, Camm J et al (2009) Consensus statement of the European heart rhythm association: updated recommendations for driving by patients with implantable cardioverter defibrillators. Europace 11:1097–1107CrossRefPubMedGoogle Scholar
  37. 37.
    Böcker D, Block M, Isbruch F et al (1995) Benefits of treatment with implantable cardioverter-defibrillators in patients with stable ventricular tachycardia without cardiac arrest. Br Heart J 73:158–163CrossRefPubMedGoogle Scholar
  38. 38.
    Freedberg NA, Hill JM, Fogel RI, Prystowsky EN (2001) Recurrence of symptomatic ventricular arrhythmias in patients with implantable cardioverter-defibrillator after the first device therapy: implications for antiarrhythmic therapy and driving restriction. CARE group. J Am Coll Cardiol 37:1910–1915CrossRefPubMedGoogle Scholar
  39. 39.
    Kou WH, Calkins H, Lewis R et al (1991) Incidence of loss of consciousness during automatic implantable cardioverter-defibrillator shocks. Ann Int Med 115:942–945)PubMedGoogle Scholar
  40. 40.
    Bänsch D, Brunn J, Castrucci M et al (1998) Syncope in patients with an implantable cardioverter-defibrillator: incidence, perdiction and implications for driving restrictions. J Am Coll Cardiol 31:608–615CrossRefPubMedGoogle Scholar
  41. 41.
    Albert CM, Rosenthal L, Calkins H et al (2007) Driving and implantable cardioverter-defibrillator shocks for ventricular arrhythmias. J Am Coll Cardiol 50:2233–2240CrossRefPubMedGoogle Scholar
  42. 42.
    Conti JB, Woodard DA, Tucker KJ et al (1997) Modification of patient driving behavior after implantation of a cardioverter defibrillator. Pacing Clin Electrophysiol 20:2200–2204CrossRefPubMedGoogle Scholar
  43. 43.
    Curtis AB, Conti JB, Tucker KJ et al (1995) Motor vehicle accidents in patients with an implantable cardioverter-defibrillator. J Am Coll Cardiol 26:180–184CrossRefPubMedGoogle Scholar
  44. 44.
    Trappe HJ, Wenzlaff P, Grellman G (1998) Should patients with implantable cardioverter defibrillators be allowed to drive? Observations in 291 patients from a single center over an 11-year period. J Interv Card Electrophysiol 2:193–201CrossRefPubMedGoogle Scholar
  45. 45.
    Akiyama T, Powell JL, Mitchell LB et al (2001) Resumption of driving after life-threatining ventricular tachyarrhythmias. N Engl J Med 345:391–397CrossRefPubMedGoogle Scholar
  46. 46.
    Larsen GC, Stupey MR, Walance CG et al (1994) Recurrent cardiac events in survivors of ventricular fibrillation or tachykardia. Implications for driving restrictions. JAMA 271:135–139CrossRefGoogle Scholar
  47. 47.
    Grubb BP (2007) Driving and implantable cardioverter-defibrillators. A clearer view. J Am Coll Cardiol 50:2241–2242CrossRefPubMedGoogle Scholar
  48. 48.
    Moss AJ, Hall WJ, Cannom DS et al (1996) Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmias. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 335:1933–1940CrossRefPubMedGoogle Scholar
  49. 49.
    Buxton AE, Lee KL, Fisher JD et al (1999) A randomizied study for the prevention of sudden death in patients with coronary artery disease. N Engl J Med 341:1882–1890CrossRefPubMedGoogle Scholar
  50. 50.
    Moss AJ, Zareba W, Hall WJ et al (2002) Multicenter automatic defibrillator implantation trial II investigators. Prophylactic implantation of defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346:877–883CrossRefPubMedGoogle Scholar
  51. 51.
    Bardy GH, Lee KL, Mark DB et al (2005) Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352:225–237CrossRefPubMedGoogle Scholar
  52. 52.
    Bristow MR, Saxon LA, Boehmer J et al (2004) Cardiac-resynchronisation therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350:2140–2150CrossRefPubMedGoogle Scholar
  53. 53.
    Packer DL, Prutkin JM, Hellkamp AS et al (2009) Impact of implantable cardioverter-defibrillator, Amiodaron, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. Circulation 120:2170–2176CrossRefPubMedGoogle Scholar
  54. 54.
    Epstein AE, Baessler CA, Curtis AB et al (2007) Addendum to „Personal and public safety issues related to arrhythmias that may affect consciousness: implications for regulation and physician recommendations: A medical/scientific statement from the American Heart Association and the North American Society of Pacing and Electrophysiology.“ Public safety issues in patients with implantable defibrillators. A scientific statement from the American Heart Association and the Heart Rhythm Society. Circulation 115:1170–1176CrossRefPubMedGoogle Scholar
  55. 55.
    Soteriades ES, Evans JC, Larson MG et al (2002) Incidence and prognosis of syncope. N Engl J Med 347:878–885CrossRefPubMedGoogle Scholar
  56. 56.
    Constantino G, Perego F, Dipaola F et al (2008) Short- and long-term prognosis of syncope, risk factors, and role of hospital admission: results from the StePS (Short-Term Prognosis of Syncope) study. J Am Coll Cardiol 51:276–283CrossRefGoogle Scholar
  57. 57.
    Sorajja D, Nesbitt GC, Hodge DO et al (2009) Syncope while driving. Clinical characteristics, causes, and prognosis. Circulation 120:928–934CrossRefPubMedGoogle Scholar
  58. 58.
    Kushner JA, Kou WH, Kadish AH, Morady F (1989) Natural history with unexplained syncope and nondiagnostic electrophysiologic study. J Am Coll Cardiol 14:391–396CrossRefPubMedGoogle Scholar
  59. 59.
    Sud S, Klein GJ, Skanes AC et al (2009) Predicting the cause of syncope from clinical history in patients undergoing prolonged monitoring. Heart Rhythm 6:238–243CrossRefPubMedGoogle Scholar
  60. 60.
    Werf F van der for the task force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (2008) Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. Eur Hear J 29:2909–2945CrossRefGoogle Scholar
  61. 61.
    Bassand J-P for the task force for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes of the European Society of Cardiology (2007) Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 28:1598–1660CrossRefPubMedGoogle Scholar
  62. 62.
    Thygesen K, Alpert JS, White HD on behalf of the joint ESC/ACCF/AHA/WHF task force for the redefinition of myocardial infarction (2007) Universal definition of myocardial infarction. Eur Heart J 28:2525–2538CrossRefPubMedGoogle Scholar
  63. 63.
    Fox KA, Dabbous OH, Goldberg RJ et al (2006) Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). B Med J 333:1091–1094CrossRefGoogle Scholar
  64. 64.
    Poole-Wilson A, Pocock SJ, Fox KAA et al (2006) Interventional versus conservative treatment in acute non-ST elevation coronary syndrome: time course of patient management and disease events over one year in the RITA 3 trial. Heart 92:1473–1479CrossRefPubMedGoogle Scholar
  65. 65.
    Solomon SD, Zelenkofske S, McMurray JJV et al (2005) Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med 352:2581–2588CrossRefPubMedGoogle Scholar
  66. 66.
    Adabag AS, Therneau TM, Gersh BJ et al (2008) Sudden death after myocardial infarction. JAMA 300:2022–2029CrossRefPubMedGoogle Scholar
  67. 67.
    Hsia J, Jablonski KA, Rice MM et al (2008) Sudden cardiac death in patients with stable coronary artery disease and preserved left ventricular systolic function. Am J Cardiol 101:457–461CrossRefPubMedGoogle Scholar
  68. 68.
    Spaulding C, Daemen J, Boersma E et al (2007) A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 356:989–997CrossRefPubMedGoogle Scholar
  69. 69.
    Goldenberg I, Jonas M, Tenenbaum A et al (2003) Current smoking, smoking cessation, and the risk of sudden cardiac death in patients with coronary artery disease. Arch Intern Med 163:2301–2305CrossRefPubMedGoogle Scholar
  70. 70.
    Daemen J, Wenaweser P, Tsuchida K et al (2007) Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369:667–678CrossRefPubMedGoogle Scholar
  71. 71.
    Pinto RP, Romerill DB, Nasser WK et al (1996) Prognosis of patients with frequent premature ventricular complexes and nonsustained ventricular tachycardia after coronary artery bypass graft surgery. Clin Cardiol 19:321–324CrossRefPubMedGoogle Scholar
  72. 72.
    Vickrey BG, Rector TS, Wickstrom SL et al (2002) Occurrence of secondary ischemic events among persons with atherosclerotic vascular disease. Stroke 33:901–906CrossRefPubMedGoogle Scholar
  73. 73.
    Davies RR, Goldstein LJ, Coady MA et al (2002) Yearly rupture or dissection rates for thoracic aortic aneurysms: simple prediction based on size. Ann Thorac Surg 73:17–27CrossRefPubMedGoogle Scholar
  74. 74.
    Davies RR, Kaple RK, Mandapati D et al (2007) Natural history of ascending aortic aneurysms in the setting of an unreplaced bicuspid aortic valve. Ann Thorac Surg 83:1338–1344CrossRefPubMedGoogle Scholar
  75. 75.
    Lederle FA (2009) The natural history of abdominal aortic aneurysm. Acta Chir Belg 109:7–12PubMedGoogle Scholar
  76. 76.
    Levy WC, Mozaffarian D, Linker DT et al (2006) The seattle heart failure model, predicition of survival in heart failure. Circulation 113:1424–1433CrossRefPubMedGoogle Scholar
  77. 77.
    Mozaffarian D, Anker SD, Anand I et al (2007) Prediction of mode of death in heart failure, the seattle heart failure model. Circulation 116:392–398CrossRefPubMedGoogle Scholar
  78. 78.
    Connolly SJ, Hallstrom AP, Cappato R et al (2000) Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. Eur Heart J 21:2071–2078CrossRefPubMedGoogle Scholar
  79. 79.
    Owan TE, Hodge DO, Herges RM et al (2006) Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355:251–259CrossRefPubMedGoogle Scholar
  80. 80.
    Massie BM, Carson PE, McMurray JJ et al (2008) Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359:2456–2467CrossRefPubMedGoogle Scholar
  81. 81.
    Yusuf S, Pfeffer MA, Swedberg K et al (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. Lancet 362:777–781CrossRefPubMedGoogle Scholar
  82. 82.
    Uretzky BF, Kormos RL, Zerbe TR et al (1992) Cardiac events after heart transplantation: incidence and predictive value of coronary arteriography. J Heart Lung Transplant 11:S45–51Google Scholar
  83. 83.
    McGiffin DC, Naftel DC, Spann JL et al (1998) Risk of death or incapacitation after heart transplantation, with particular reference to pilots. J Heart Lung Transplant 17:497–504PubMedGoogle Scholar
  84. 84.
    Maron BJ, Casey SA, Poliac LC et al (1999) Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 281:650–655CrossRefPubMedGoogle Scholar
  85. 85.
    Spirito P, Autore C, Rapezzi C et al (2009) syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation 119:1703–1710CrossRefPubMedGoogle Scholar
  86. 86.
    Ammash NM, Seward JB, Bailey KR et al (2000) Clinical profile and outcome of idiopathic restrictive cardiomyopathy. Circulation 101:2490–2496PubMedGoogle Scholar
  87. 87.
    Brugada J, Brugada R, Brugada P (2003) Determinants of sudden cardiac death in individuals with the electrocardiographic pattern of Brugada syndrome and no previous cardiac arrest. Circulation 108:3092–3096CrossRefPubMedGoogle Scholar
  88. 88.
    Hobbs JB, Peterson DR, Moss AJ et al (2006) Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syndrome. JAMA 296:1249–1254CrossRefPubMedGoogle Scholar
  89. 89.
    Hulot JS, Jouven X, Empana JP et al (2004) Natural history and risk stratification of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circulation 110:1879–1884CrossRefPubMedGoogle Scholar
  90. 90.
    Chizner MA, Pearle DL, Leon AC de (1980) The natural history of aortic stenosis in adults. Am Heart J 99:419–424CrossRefPubMedGoogle Scholar
  91. 91.
    Kitiyakara C, Guzman NJ (1998) Malignant hypertension and hypertensive emergencies. J Am Soc Nephrol 9:133–142PubMedGoogle Scholar
  92. 92.
    Faulhaber H-D, Bansi D (1985) Begutachtung der Fahrtauglichkeit bei arterieller Hypertonie. Z Ärztl. Fortbild 79:755–757Google Scholar
  93. 93.
    Erbel R, Lüderitz B (1999) Fahrerlaubnis aus Sicht des Kardiologen, Z Kardiol 88:154–161Google Scholar
  94. 94.
    Epstein AE, Miles WM, Benditt DG et al (1996) Personal and public safety issues related to arrhythmias that may affect consciousness:implications for regulation and physician recommendations. Circulation 94:1147–1166PubMedGoogle Scholar
  95. 95.
    Vardas PE (für die Mitglieder der Task Force) (2007) Guidelines for cardiac pacing and cardiac resynchronisation therapy. Europace 9:959–998CrossRefPubMedGoogle Scholar
  96. 96.
    Blumenthal R, Braunstein J, Connolly H et al (2002) Cardiovascular advisory panel guidelines for the medical examination of commercial motor vehicle drivers. US department of transportation, federal motor carrier safety administration. Report No. FMCSA-MCP-02–002. Abrufbar unter http://www.fmcsa.dot.gov/documents/cardio.pdfGoogle Scholar
  97. 97.
    Garrahy P, McAlister H, Hossack K (2002) Cardiovascular disease and driving. http://www.csanz.edu.au/guidelines/practice/Drivegl/2002.pdfGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • H.H. Klein
    • 1
    Email author
  • A. Krämer
    • 2
  • B.M. Pieske
    • 3
  • H.-J. Trappe
    • 4
  • H. de Vries
    • 5
  1. 1.Med. Klinik II, Schwerpunkt KardiologieKlinikum Idar-Oberstein GmbHIdar-ObersteinDeutschland
  2. 2.Kardiologische Praxis SiegenSiegenDeutschland
  3. 3.Klinische Abteilung für KardiologieMedizinische Universitätsklinik GrazGrazÖsterreich
  4. 4.Marienhospital HerneRuhr Universität BochumHerneDeutschland
  5. 5.Landgericht BonnBonnDeutschland

Personalised recommendations